Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serum cholesterol in treatment-resistant depression.

George I Papakostas1, Timothy Petersen, Shamsah B Sonawalla

  • 1Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. gpapakostas@partners.org

Neuropsychobiology
|May 22, 2003
PubMed
Summary

Elevated cholesterol levels in patients with major depressive disorder (MDD) predict poor response to nortriptyline treatment, particularly in those with treatment-resistant depression (TRD). This finding highlights hypercholesterolemia as a factor in MDD treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How do network structures of depressive symptoms differ between asian patients with bipolar depression and those with unipolar depression?

Asian journal of psychiatry·2026
Same author

Prevalence of GLP-1 Receptor Agonist Use Among Privately Insured Individuals With Mood Disorders.

The Journal of clinical psychiatry·2026
Same author

The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD<sup>✰</sup>.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.

JAMA psychiatry·2026
Same author

Lithium effects on renal functioning: an expert opinion and management algorithm.

International journal of bipolar disorders·2026
Same author

All-Cause and Cause-Specific Mortality in Patients With Bipolar II Disorder.

JAMA network open·2026

Area of Science:

  • Neuroscience
  • Psychiatry
  • Biochemistry

Background:

  • Major depressive disorder (MDD) is associated with altered cholesterol metabolism.
  • Previous research indicated elevated cholesterol predicts poor fluoxetine response in MDD patients.
  • Limited data exists on cholesterol levels in treatment-resistant depression (TRD).

Purpose of the Study:

  • Compare baseline cholesterol and triglyceride levels between MDD patients with and without TRD.
  • Investigate if baseline cholesterol predicts treatment response in TRD patients receiving nortriptyline (NT).

Main Methods:

  • A 6-week open-label trial of nortriptyline (NT) was conducted for 92 TRD patients.
  • Baseline cholesterol and triglyceride levels were analyzed for 59 patients.

Related Experiment Videos

  • Logistic regression was used to assess cholesterol's predictive value for NT response in TRD patients, controlling for age and gender.

    • Main Results:

    • TRD patients exhibited higher baseline triglyceride levels than non-TRD patients.
    • Elevated cholesterol (≥200 mg/dl) at baseline predicted a poor response to a 6-week course of nortriptyline in TRD patients.

    Conclusions:

    • Hypercholesterolemia is confirmed to be associated with poor treatment outcomes in major depressive disorder, especially in TRD.
    • Baseline cholesterol levels may serve as a predictive biomarker for treatment response in MDD patients undergoing nortriptyline therapy.